Abstract is: Edaravone, sold under the brand name Radicava among others, is a medication used to treat stroke and amyotrophic lateral sclerosis (ALS). It is given by intravenous infusion and by mouth. The most common side effects include bruising (contusions), problems walking (gait disturbances), and headaches. The mechanism by which edaravone might be effective is unknown. The medication is known to be an antioxidant, and oxidative stress has been hypothesized to be part of the process that kills neurons in people with ALS. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
| P3780 | active ingredient in | Radicava | Q47522060 |
| P703 | found in taxon | Homo sapiens | Q15978631 |
| P366 | has use | medication | Q12140 |
| P8026 | LiverTox likelihood score | LiverTox toxicity likelihood category E | Q83284667 |
| P2067 | mass | 174.079 | |
| P2175 | medical condition treated | amyotrophic lateral sclerosis | Q206901 |
| P2101 | melting point | 127 | |
| 129 | |||
| P2868 | subject has role | free radical scavengers | Q25401178 |
| Q93214911 | A Study of TTYP01 in Healthy Adult Subjects |
| Q113914280 | Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects |
| Q86260785 | Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy |
| Q113888922 | Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study) |
| Q106642467 | Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube |
| Q113912841 | Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows |
| Q105493134 | Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage |
| Q113925849 | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS |
| Q100788496 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS |
| Q61921601 | Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) |
| Q62062061 | PK Study in Subjects With Severe Hepatic Impairment |
| Q86249508 | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) |
| Q113893332 | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) |
| Q113919543 | Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke (2021-09-30) |
| Q99082124 | Study of Oral Edaravone in Healthy Adult Males |
| Q94726213 | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS |
| Q113944717 | Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2) |
| Q47657618 | (+)-Borneol improves the efficacy of edaravone against DSS-induced colitis by promoting M2 macrophages polarization via JAK2-STAT3 signaling pathway |
| Q90217985 | 2-Methyl-5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-imine, an edaravone analog, exerts neuroprotective effects against acute ischemic injury via inhibiting oxidative stress |
| Q44623943 | A Free Radical Scavenger, Edaravone, Attenuates Steatosis and Cell Death via Reducing Inflammatory Cytokine Production in Rat Acute Liver Injury |
| Q53406943 | A Novel LC-MS-MS Method With an Effective Antioxidant for the Determination of Edaravone, a Free-Radical Scavenger in Dog Plasma and its Application to a Pharmacokinetic Study. |
| Q46602751 | A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone |
| Q40213598 | A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient |
| Q43096243 | A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury |
| Q46253863 | A comparison of protective effect of propofol and edaravone pretreatment against cerebral ischemia-reperfusion injury |
| Q33938450 | A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? |
| Q39427640 | A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model |
| Q46488342 | A free radical scavenger, edaravone (MCI-186), diminishes intestinal neutrophil lipid peroxidation and bacterial translocation in a rat hemorrhagic shock model |
| Q46783772 | A free radical scavenger, edaravone, inhibits lipid peroxidation and the production of nitric oxide in hypoxic-ischemic brain damage of neonatal rats |
| Q46369232 | A free radical scavenger, edaravone, prevents ischemia-reperfusion injury in liver grafts from non-heart-beating donors |
| Q84096278 | A hypothesis: Edaravone exert cardioprotection partly via modulation of adiponectin |
| Q46934507 | A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox |
| Q44968170 | A new free radical scavenger, edaravone, ameliorates oxidative liver damage due to ischemia-reperfusion in vitro and in vivo |
| Q35193649 | A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion |
| Q46149348 | A novel administration route for edaravone: I. Effects of metabolic inhibitors on skin permeability of edaravone |
| Q43181376 | A novel administration route of edaravone--II: mucosal absorption of edaravone from edaravone/hydroxypropyl-beta-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite |
| Q46129348 | A novel fluorescent assay for edaravone with aqueous functional CdSe quantum dots |
| Q50222471 | A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis |
| Q58775994 | A radical scavenger edaravone and oligodendrocyte protection/regeneration |
| Q33748058 | A radical scavenger edaravone inhibits matrix metalloproteinase-9 upregulation and blood-brain barrier breakdown in a mouse model of prolonged cerebral hypoperfusion |
| Q46616469 | A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation |
| Q35121559 | A randomized controlled clinical trial to compare the safety and efficacy of edaravone in acute ischemic stroke |
| Q47782666 | A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies |
| Q44614183 | A theoretical investigation on DPPH radical-Scavenging mechanism of edaravone |
| Q42257517 | Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry |
| Q46065414 | Acute urinary retention and subsequent catheterization cause lipid peroxidation and oxidative DNA damage in the bladder: preventive effect of edaravone, a free-radical scavenger |
| Q85034903 | Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study |
| Q46463420 | Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism |
| Q48364280 | Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury. |
| Q44759401 | Alterations of antiproliferative effects of serum obtained from patients with acute cerebral infarction treated with a radical scavenger, edaravone, with or without amlodipine using an in vitro cultured basilar artery smooth muscle cells |
| Q37108311 | Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction |
| Q46514766 | Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats |
| Q34584715 | Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia |
| Q83423930 | Antifibrotic effect of edaravone in rat liver cirrhosis induced by dimethylnitrosamine |
| Q84523359 | Antioxidant treatment with edaravone or taurine ameliorates diabetes-induced testicular dysfunction in the rat |
| Q88110411 | Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone |
| Q47957937 | Attenuation of axonal injury and oxidative stress by edaravone protects against cognitive impairments after traumatic brain injury |
| Q33217880 | Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model |
| Q44024185 | Attenuation of ischemia/reperfusion-induced ovarian damage in rats: does edaravone offer protection? |
| Q91912912 | Author response to a Letter to the Editor entitled: Edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin) |
| Q39337905 | Benchmarking the DFT methodology for assessing antioxidant-related properties: quercetin and edaravone as case studies. |
| Q91623627 | Beneficial effects of edaravone in experimental model of amitriptyline-induced cardiotoxicity in rats |
| Q50697479 | Beneficial effects of edaravone on the expression of serum matrix metalloproteinase-9 after cerebral hemorrhage. |
| Q41841037 | Beneficial effects of edaravone, a novel antioxidant, in rats with dilated cardiomyopathy |
| Q38042627 | Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review). |
| Q37933081 | Beyond neurological disease: new targets for edaravone (Review). |
| Q57155471 | Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers |
| Q95514380 | CADTH Canadian Drug Expert Committee Recommendation: Edaravone (Radicava — Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis |
| Q53585843 | Cardioprotective effect of edaravone against ischaemia-reperfusion injury in the rabbit heart before, during and after reperfusion treatment. |
| Q39310557 | Cardioprotective effect of edaravone pharmacological postconditioning on acute myocardial ischemia/reperfusion injury: experiment with rats |
| Q91518685 | Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone |
| Q41843739 | Chemical repair activity of free radical scavenger edaravone: reduction reactions with dGMP hydroxyl radical adducts and suppression of base lesions and AP sites on irradiated plasmid DNA |
| Q88936556 | Chitosan/hyaluronan/edaravone membranes for anti-inflammatory wound dressing: In vitro and in vivo evaluation studies |
| Q91449184 | Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy |
| Q95514365 | Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis |
| Q37034277 | Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance |
| Q92563408 | Clinical and Pathological Benefits of Edaravone for Alzheimer's Disease with Chronic Cerebral Hypoperfusion in a Novel Mouse Model |
| Q39240053 | Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. |
| Q44582333 | Clinical evaluation of liver injury in patients with acute ischemic brain stroke treated with edaravone |
| Q90679036 | Clinical observation in edaravone treatment for acute cerebral infarction |
| Q44471241 | Clinical usefulness of edaravone for acute liver injury |
| Q41886952 | Combination Therapy Using tPA and Edaravone Improves the Neurotoxic Effect of tPA. |
| Q38498453 | Combination drug therapy using edaravone and Daio-Orengedoku-to after transient focal ischemia in rats |
| Q46520745 | Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice |
| Q40967330 | Combination of edaravone and neural stem cell transplantation repairs injured spinal cord in rats |
| Q44035169 | Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils |
| Q86999095 | Combined edaravone and D1-3-n-butylphthalide antioxidant therapy for paraquat poisoning |
| Q83832447 | Combined effects of a neutrophil elastase inhibitor (sivelestat sodium) and a free radical scavenger (edaravone) on lipopolysaccharide-induced acute lung injury in rats |
| Q47827577 | Compound edaravone alleviates lipopolysaccharide (LPS)-induced acute lung injury in mice. |
| Q34699979 | Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients |
| Q47722540 | Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction |
| Q50316805 | Could edaravone prevent gentamicin ototoxicity? An experimental study |
| Q49824009 | Curative efficacy of penehyclidine combined with edaravone on acute cerebral infarction and their effects on serum TNF-α and NDS score in rats |
| Q48335097 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy |
| Q41915708 | Density functional theory (DFT) study of edaravone derivatives as antioxidants |
| Q46213220 | Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone |
| Q86543464 | Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma |
| Q47851842 | Development of a novel oral delivery system of edaravone for enhancing bioavailability |
| Q45994514 | Development of cardiac dysfunction induced by repetitive transient myocardial ischemia is inhibited by edaravone in conscious rats. |
| Q47547271 | Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective |
| Q35849431 | Diversification of edaravone via palladium-catalyzed hydrazine cross-coupling: Applications against protein misfolding and oligomerization of beta-amyloid |
| Q48364186 | Does edaravone (MCI- 186) act as an antioxidant and a neuroprotector in experimental traumatic brain injury? |
| Q43161921 | Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy |
| Q41824117 | Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model? |
| Q89118446 | Dose-dependency of multiple free radical-scavenging activity of edaravone |
| Q42774046 | ERK1/2 mediates edaravone-triggered protection against myocardial damage induced by isoprenaline in H9c2 cells |
| Q48651842 | Early Combined Therapy with Pharmacologically Induced Hypothermia and Edaravone Exerts Neuroprotective Effects in a Rat Model of Intracerebral Hemorrhage |
| Q91736536 | Early post-marketing experience with edaravone in an unselected group of patients with ALS |
| Q95582012 | Edaravone |
| Q56911324 | Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases |
| Q34578581 | Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. |
| Q37384616 | Edaravone (MCI-186) is effective as a free radical scavenger following arteriovenous sheathotomy for treatment of macular oedema associated with branch retinal vein occlusion |
| Q46184515 | Edaravone (MCI-186) scavenges reactive oxygen species and ameliorates tissue damage in the murine spinal cord injury model |
| Q46531050 | Edaravone (MCI-186), a free radical scavenger, attenuates retinal ischemia/reperfusion injury in rats |
| Q95423899 | Edaravone (Radicava) for ALS |
| Q49377977 | Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis |
| Q42408578 | Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke |
| Q46074658 | Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). |
| Q50803493 | Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). |
| Q91150122 | Edaravone Administration Confers Neuroprotection after Experimental Intracerebral Hemorrhage in Rats via NLRP3 Suppression |
| Q89536675 | Edaravone Ameliorates Renal Warm Ischemia-Reperfusion Injury by Downregulating Endoplasmic Reticulum Stress in a Rat Resuscitation Model |
| Q46294885 | Edaravone Attenuates the Proinflammatory Response in Amyloid-β-Treated Microglia by Inhibiting NLRP3 Inflammasome-Mediated IL-1β Secretion |
| Q55128459 | Edaravone Improves Septic Cardiac Function by Inducing an HIF-1α/HO-1 Pathway. |
| Q34183144 | Edaravone Mitsubishi-Tokyo |
| Q46296061 | Edaravone Prevents Retinal Degeneration in Adult Mice Following Optic Nerve Injury |
| Q89960504 | Edaravone Protects against Pancreatic and Intestinal Injury after Acute Pancreatitis via Nuclear Factor-κB Signaling in Mice |
| Q89426747 | Edaravone Reduces Hyperperfusion-Related Neurological Deficits in Adult Moyamoya Disease: Historical Control Study |
| Q57181540 | Edaravone Reduces Iron-Mediated Hydrocephalus and Behavioral Disorder in Rat by Activating the Nrf2/HO-1 Pathway |
| Q41890158 | Edaravone Suppresses Reperfusion Injury following Leg Ischemia in Rats: A Transmission Electron Microscopic Study |
| Q47600546 | Edaravone abrogates LPS-induced behavioral anomalies, neuroinflammation and PARP-1. |
| Q61454050 | Edaravone acts as a potential therapeutic drug against pentylenetetrazole-induced epilepsy in male albino rats by downregulating cyclooxygenase-II |
| Q91954884 | Edaravone administration in pivotal clinical Study 19 |
| Q35549137 | Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits |
| Q48455247 | Edaravone alleviates cisplatin-induced neurobehavioral deficits via modulation of oxidative stress and inflammatory mediators in the rat hippocampus. |
| Q83222513 | Edaravone alleviates delayed neuronal death and long-dated cognitive dysfunction of hippocampus after transient focal ischemia in Wistar rat brains |
| Q44715325 | Edaravone alleviates hypoxia-acidosis/reoxygenation-induced neuronal injury by activating ERK1/2. |
| Q91736041 | Edaravone alleviates oxidative stress and apoptosis of intestinal epithelium after burns via MAPK pathway |
| Q46301863 | Edaravone ameliorates compression-induced damage in rat nucleus pulposus cells |
| Q83814507 | Edaravone ameliorates diabetes-induced dysfunction of NO-induced relaxation in corpus cavernosum smooth muscle in the rat |
| Q90860811 | Edaravone ameliorates experimental autoimmune thyroiditis in rats through HO-1-dependent STAT3/PI3K/Akt pathway |
| Q86082232 | Edaravone ameliorates oxidative damage associated with Aβ25-35 treatment in PC12 cells |
| Q42507233 | Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat. |
| Q46826907 | Edaravone ameliorates the adverse effects of valproic acid toxicity in small intestine |
| Q54099433 | Edaravone and Its Protective Effects against Disease Progression in Neurological Conditions Besides Strokes. |
| Q93254440 | Edaravone and MAPK pathway: the key role of gut permeability |
| Q90826448 | Edaravone and benidipine protect myocardial damage by regulating mitochondrial stress, apoptosis signalling and cardiac biomarkers against doxorubicin-induced cardiotoxicity |
| Q54392309 | Edaravone and carnosic acid synergistically enhance the expression of nerve growth factor in human astrocytes under hypoxia/reoxygenation. |
| Q89490292 | Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke |
| Q47782687 | Edaravone and its clinical development for amyotrophic lateral sclerosis |
| Q92508661 | Edaravone at high concentrations attenuates cognitive dysfunctions induced by abdominal surgery under general anesthesia in aged mice |
| Q42467702 | Edaravone attenuates brain damage in rats after acute CO poisoning through inhibiting apoptosis and oxidative stress |
| Q46838344 | Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage |
| Q43279610 | Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. |
| Q89495829 | Edaravone attenuates experimental asthma in mice through induction of HO-1 and the Keap1/Nrf2 pathway |
| Q40560509 | Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2/HO-1 pathway |
| Q82870684 | Edaravone attenuates hydroxyl radical stress and augmented angiotensin II response in diabetic rats |
| Q48710019 | Edaravone attenuates impairment of synaptic plasticity in granule cell layer of the dentate gyrus following traumatic brain injury |
| Q48234772 | Edaravone attenuates intracerebroventricular streptozotocin-induced cognitive impairment in rats. |
| Q46265761 | Edaravone attenuates ischemia-reperfusion injury by inhibiting oxidative stress in a canine lung transplantation model. |
| Q47441751 | Edaravone attenuates lipopolysaccharide-induced acute respiratory distress syndrome associated early pulmonary fibrosis via amelioration of oxidative stress and transforming growth factor-β1/Smad3 signaling |
| Q91070497 | Edaravone attenuates lung injury in a hind limb ischemia-reperfusion rat model: A histological, immunohistochemical and biochemical study |
| Q38837055 | Edaravone attenuates monocyte adhesion to endothelial cells induced by oxidized low-density lipoprotein |
| Q52596294 | Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway. |
| Q47802895 | Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway |
| Q42045974 | Edaravone attenuates paraquat-induced lung injury by inhibiting oxidative stress in human type II alveolar epithelial cells |
| Q91689558 | Edaravone attenuates traumatic brain injury through anti-inflammatory and anti-oxidative modulation |
| Q46028176 | Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model. |
| Q35356878 | Edaravone combined with Schwann cell transplantation may repair spinal cord injury in rats |
| Q92308846 | Edaravone combined with cinepazide maleate on neurocyte autophagy and neurological function in rats with subarachnoid hemorrhage |
| Q42172859 | Edaravone decreases paraquat toxicity in a549 cells and lung isolated mitochondria. |
| Q46180484 | Edaravone derivatives containing NO-donor functions |
| Q46935468 | Edaravone diminishes free radicals from circulating neutrophils in patients with ischemic brain attack |
| Q33547232 | Edaravone directly reacts with singlet oxygen and protects cells from attack |
| Q41417536 | Edaravone enhances brain-derived neurotrophic factor production in the ischemic mouse brain |
| Q50995064 | Edaravone enhances the viability of ischemia/reperfusion flaps. |
| Q24236629 | Edaravone for acute intracerebral haemorrhage |
| Q24240836 | Edaravone for acute intracerebral haemorrhage |
| Q24234306 | Edaravone for acute ischaemic stroke |
| Q24242631 | Edaravone for acute ischaemic stroke |
| Q30671072 | Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials |
| Q91505711 | Edaravone for amyotrophic lateral sclerosis: More evidence for long-term benefit |
| Q94554786 | Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics |
| Q83390216 | Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress |
| Q91955956 | Edaravone for the treatment of amyotrophic lateral sclerosis |
| Q24202093 | Edaravone for traumatic brain injury |
| Q50048110 | Edaravone for treatment of early-stage ALS - Authors' reply |
| Q50048103 | Edaravone for treatment of early-stage ALS. |
| Q27335848 | Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease |
| Q38154741 | Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review |
| Q33847233 | Edaravone improves spatial memory and modulates endoplasmic reticulum stress-mediated apoptosis after abdominal surgery in mice |
| Q48619839 | Edaravone improves survival and neurological outcomes after CPR in a ventricular fibrillation model of rats |
| Q43231952 | Edaravone improves the expression of nerve growth factor in human astrocytes subjected to hypoxia/reoxygenation |
| Q46534472 | Edaravone improves the survival of rats subjected to hemorrhagic shock without resuscitation |
| Q46088999 | Edaravone in ALS. |
| Q48593479 | Edaravone in acute ischemic stroke |
| Q88150521 | Edaravone in the treatment of amyotrophic lateral sclerosis |
| Q95523968 | Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion |
| Q34657556 | Edaravone increases regional cerebral blood flow after traumatic brain injury in mice |
| Q46107036 | Edaravone inhibits DNA peroxidation and neuronal cell death in neonatal hypoxic-ischemic encephalopathy model rat. |
| Q48593535 | Edaravone inhibits JNK-c-Jun pathway and restores anti-oxidative defense after ischemia-reperfusion injury in aged rats |
| Q44931712 | Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney |
| Q42243247 | Edaravone inhibits apoptosis caused by ischemia/reperfusion injury in a porcine hepatectomy model |
| Q59350153 | Edaravone inhibits autophagy after neuronal oxygen-glucose deprivation/recovery injury |
| Q80608140 | Edaravone inhibits collagen-induced arthritis possibly through suppression of nuclear factor-kappa B |
| Q38993738 | Edaravone inhibits hypoxia-induced trophoblast-soluble Fms-like tyrosine kinase 1 expression: a possible therapeutic approach to preeclampsia |
| Q48284145 | Edaravone inhibits lipid peroxidation in neonatal hypoxic-ischemic rats: an in vivo microdialysis study |
| Q42776028 | Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor |
| Q90677567 | Edaravone inhibits procaspase-3 denitrosylation and activation through FasL-Trx2 pathway in KA-induced seizure |
| Q43282511 | Edaravone inhibits protein carbonylation by a direct carbonyl-scavenging mechanism: focus on reactivity, selectivity, and reaction mechanisms |
| Q46877741 | Edaravone inhibits rheumatoid synovial cell proliferation and migration |
| Q92992448 | Edaravone inhibits the conformational transition of amyloid-β42: insights from molecular dynamics simulations |
| Q83193515 | Edaravone inhibits the disease activity in rheumatoid arthritis |
| Q46986504 | Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia |
| Q39979776 | Edaravone inhibits the induction of iNOS gene expression at transcriptional and posttranscriptional steps in murine macrophages |
| Q34213089 | Edaravone injected at the start of reperfusion suppresses myonephropathic metabolic syndrome in rats |
| Q50578510 | Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease. |
| Q39173214 | Edaravone injection reverses learning and memory deficits in a rat model of vascular dementia |
| Q46318400 | Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model |
| Q35971126 | Edaravone is a free radical scavenger that protects against laser-induced choroidal neovascularization in mice and common marmosets |
| Q38847362 | Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress |
| Q46042646 | Edaravone may be an efficacious adjunctive therapeutic agent for decompression sickness: an editorial perspective |
| Q89799187 | Edaravone may prevent ferroptosis in ALS |
| Q58366514 | Edaravone mimics sphingosine-1-phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells |
| Q35617219 | Edaravone mitigates hexavalent chromium-induced oxidative stress and depletion of antioxidant enzymes while estrogen restores antioxidant enzymes in the rat ovary in F1 offspring |
| Q46925680 | Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats |
| Q40898682 | Edaravone offers neuroprotection for acute diabetic stroke patients |
| Q45846630 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress |
| Q92175166 | Edaravone presents antidepressant-like activity in corticosterone model of depression in mice with possible role of Fkbp5, Comt, Adora1 and Slc6a15 genes |
| Q80847306 | Edaravone preserves coronary microvascular endothelial function after ischemia/reperfusion on the beating canine heart in vivo |
| Q46555407 | Edaravone prevented deteriorated cardiac function after myocardial ischemia-reperfusion via inhibiting lipid peroxidation in rat. |
| Q46818788 | Edaravone prevents Fas-induced fulminant hepatic failure in mice by regulating mitochondrial Bcl-xL and Bax. |
| Q46120258 | Edaravone prevents bowel infarction after acute superior mesenteric artery thromboembolism using autologous fibrin clots in a rabbit model |
| Q46851342 | Edaravone prevents iNOS expression by inhibiting its promoter transactivation and mRNA stability in cytokine-stimulated hepatocytes |
| Q46649289 | Edaravone prevents kainic acid-induced neuronal death |
| Q46801984 | Edaravone prevents lung injury induced by hepatic ischemia-reperfusion |
| Q92099188 | Edaravone prevents memory impairment in an animal model of post-traumatic distress |
| Q39154570 | Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease |
| Q46567320 | Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model |
| Q34412765 | Edaravone promotes functional recovery after mechanical peripheral nerve injury |
| Q92245999 | Edaravone promotes nerve function recovery after acute cerebral infarction in rats via targeting Keap1-Nrf2/ARE |
| Q35181567 | Edaravone protect against retinal damage in streptozotocin-induced diabetic mice. |
| Q39175794 | Edaravone protected PC12 cells against MPP(+)-cytoxicity via inhibiting oxidative stress and up-regulating heme oxygenase-1 expression |
| Q28533889 | Edaravone protected human brain microvascular endothelial cells from methylglyoxal-induced injury by inhibiting AGEs/RAGE/oxidative stress |
| Q34518037 | Edaravone protects HT22 neurons from H2O2-induced apoptosis by inhibiting the MAPK signaling pathway. |
| Q33253924 | Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondria |
| Q46471698 | Edaravone protects against MPP+ -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway |
| Q43273759 | Edaravone protects against apoptotic neuronal cell death and improves cerebral function after traumatic brain injury in rats |
| Q38774540 | Edaravone protects against cobalt chloride-induced dysfunctions in apoptosis and invasion in trophoblast cells |
| Q51016480 | Edaravone protects against glutamate-induced PERK/EIF2α/ATF4 integrated stress response and activation of caspase-12. |
| Q36323797 | Edaravone protects against hyperosmolarity-induced oxidative stress and apoptosis in primary human corneal epithelial cells |
| Q44922440 | Edaravone protects against hypoxia/ischemia-induced endoplasmic reticulum dysfunction |
| Q46757300 | Edaravone protects against ischemia/reperfusion-induced functional and biochemical changes in rat urinary bladder |
| Q44371435 | Edaravone protects against ischemia/reperfusion-induced oxidative damage to mitochondria in rat liver |
| Q45209858 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. |
| Q27322912 | Edaravone protects against methylglyoxal-induced barrier damage in human brain endothelial cells |
| Q37715343 | Edaravone protects against oxygen-glucose-serum deprivation/restoration-induced apoptosis in spinal cord astrocytes by inhibiting integrated stress response. |
| Q34175321 | Edaravone protects against tissue damage in the lung and kidney induced by myonephropathic metabolic syndrome |
| Q28570114 | Edaravone protects cortical neurons from apoptosis by inhibiting the translocation of BAX and Increasing the interaction between 14-3-3 and p-BAD |
| Q37696797 | Edaravone protects endotoxin-induced liver injury by inhibiting apoptosis and reducing proinflammatory cytokines |
| Q92984723 | Edaravone protects from memory impairment induced by chronic L-methionine administration |
| Q92470974 | Edaravone protects from retinal injury through NF-κB in diabetic rats |
| Q41913123 | Edaravone protects human peripheral blood lymphocytes from γ-irradiation-induced apoptosis and DNA damage |
| Q48706360 | Edaravone protects neurons in the rat substantia nigra against 6-hydroxydopamine-induced oxidative stress damage |
| Q38852430 | Edaravone protects osteoblastic cells from dexamethasone through inhibiting oxidative stress and mPTP opening |
| Q90035028 | Edaravone protects primary-cultured rat cortical neurons from ketamine-induced apoptosis via reducing oxidative stress and activating PI3K/Akt signal pathway |
| Q94554811 | Edaravone protects rat astrocytes from oxidative or neurotoxic inflammatory insults by restoring Akt/Bcl-2/Caspase-3 signaling axis |
| Q53536668 | Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence. |
| Q51614987 | Edaravone protects rats and human pulmonary alveolar epithelial cells against hyperoxia injury: heme oxygenase-1 and PI3K/Akt pathway may be involved. |
| Q46283159 | Edaravone protects the retina against ischemia/reperfusion‑induced oxidative injury through the PI3K/Akt/Nrf2 pathway |
| Q46980060 | Edaravone protects the vestibular periphery from free radical-induced toxicity in response to perilymphatic application of (+/-)-alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid |
| Q91623960 | Edaravone reduces Aβ-induced oxidative damage in SH-SY5Y cells by activating the Nrf2/ARE signaling pathway |
| Q47376779 | Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus |
| Q46069792 | Edaravone reduces brain oedema and attenuates cell death after intracerebral haemorrhage in mice |
| Q89810080 | Edaravone reduces depression severity in patients with symptomatic intracranial stenosis and is associated with the serum expression of sex hormones |
| Q46706351 | Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain |
| Q79300361 | Edaravone reduces ischemia-reperfusion injury mediators in rat liver |
| Q34220872 | Edaravone reduces mitochondrial damage due to reperfusion injury following leg ischemia in rats |
| Q47317382 | Edaravone reduces myocardial infarct size and improves cardiac function and remodelling in rabbits |
| Q91909936 | Edaravone reduces oxidative stress and intestinal cell apoptosis after burn through up-regulating miR-320 expression |
| Q47907248 | Edaravone rescues the lung by inhibiting lipid peroxidation and pro-inflammatory cytokines in a rat model |
| Q89105249 | Edaravone suppresses degradation of type II collagen |
| Q34220743 | Edaravone suppresses endothelial cell injury in vein grafts of a rat model |
| Q37321607 | Edaravone suppresses postoperative reperfusion injury in rat lower extremity: An immunohistological study |
| Q41335619 | Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma. |
| Q48416951 | Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). |
| Q28550314 | Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse |
| Q47137226 | Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis. |
| Q89406070 | Edaravone, a cytoprotective drug, enhances transgene expression mediated by lipoplexes in HepG2 cells and mice |
| Q40270801 | Edaravone, a free radical scavenger, accelerates wound healing in diabetic mice |
| Q39968343 | Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis |
| Q50985388 | Edaravone, a free radical scavenger, attenuates behavioral deficits following transient forebrain ischemia by inhibiting oxidative damage in gerbils. |
| Q48972289 | Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia |
| Q50687872 | Edaravone, a free radical scavenger, improves the graft viability on liver transplantation from non-heart-beating donors in pigs. |
| Q45943643 | Edaravone, a free radical scavenger, in the treatment of idiopathic sudden sensorineural hearing loss with profound hearing loss. |
| Q46190589 | Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator |
| Q46231881 | Edaravone, a free radical scavenger, is effective on neuropathic pain in rats |
| Q36072706 | Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats. |
| Q53296151 | Edaravone, a free radical scavenger, promotes engraftment of intraportally transplanted islet cells. |
| Q93075194 | Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro |
| Q39886023 | Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo |
| Q41837296 | Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro |
| Q52649995 | Edaravone, a free radical scavenger, protects neuronal cells' mitochondria from ischemia by inactivating another new critical factor of the 5-lipoxygenase pathway affecting the arachidonic acid metabolism. |
| Q45762623 | Edaravone, a free radical scavenger, retards the development of amygdala kindling in rats |
| Q83639885 | Edaravone, a hydroxyl radical scavenger, ameliorates the severity of pulmonary hypertension in a porcine model of neonatal sepsis |
| Q39749372 | Edaravone, a known free radical scavenger, enhances X-ray-induced apoptosis at low concentrations |
| Q44679488 | Edaravone, a newly developed radical scavenger, protects against ischemia-reperfusion injury of the small intestine in rats |
| Q42839906 | Edaravone, a novel antidote against lung injury and pulmonary fibrosis induced by paraquat? |
| Q44572914 | Edaravone, a novel free radical scavenger, prevents liver injury and mortality in rats administered endotoxin |
| Q85506347 | Edaravone, a novel free radical scavenger, prevents steroid-induced osteonecrosis in rabbits |
| Q46084103 | Edaravone, a novel free radical scavenger, reduces high-mobility group box 1 and prolongs survival in a neonatal sepsis model |
| Q45273958 | Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase |
| Q54215643 | Edaravone, a potent free radical scavenger and a calcium channel blocker attenuate isoproterenol induced myocardial infarction by suppressing oxidative stress, apoptotic signaling and ultrastructural damage. |
| Q46927416 | Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death |
| Q53769400 | Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. |
| Q48216592 | Edaravone, a radical scavenger, inhibits mitochondrial permeability transition pore in rat brain |
| Q44674487 | Edaravone, a radical scavenger, may enhance or produce antiproliferative effects of fluvastatin, amlodipine, ozagrel, GF109203X and Y27632 on cultured basilar artery smooth muscle cells |
| Q35027698 | Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment. |
| Q37738220 | Edaravone-Encapsulated Agonistic Micelles Rescue Ischemic Brain Tissue by Tuning Blood-Brain Barrier Permeability. |
| Q91982339 | Edaravone-Loaded Alginate-Based Nanocomposite Hydrogel Accelerated Chronic Wound Healing in Diabetic Mice |
| Q92676690 | Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression |
| Q39489043 | Edaravone-loaded liposome eyedrops protect against light-induced retinal damage in mice. |
| Q39595936 | Edaravone-loaded liposomes for retinal protection against oxidative stress-induced retinal damage |
| Q47988417 | Edaravone: A new drug approved for ALS. |
| Q42345783 | Edaravone: a baby in the bathwater? |
| Q89583589 | Edaravone: a new hope for deadly amyotrophic lateral sclerosis |
| Q42930564 | Edaravone: a new therapeutic approach for the treatment of acute stroke |
| Q59557491 | Edaravone: a new treatment for ALS on the horizon? |
| Q92522027 | Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke |
| Q46110518 | Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage |
| Q82704967 | Effect of a free radical scavenger, edaravone, on free radical reactions: related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model |
| Q44418044 | Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters |
| Q46634254 | Effect of a novel free radical scavenger, edaravone, on puromycin aminonucleoside induced nephrosis in rats |
| Q91827213 | Effect of edaravone against cisplatin-induced chronic renal injury |
| Q42434867 | Effect of edaravone in diabetes mellitus-induced nephropathy in rats |
| Q83330904 | Effect of edaravone on Aβ1-40 induced enhancement of voltage-gated calcium channel current |
| Q43917438 | Effect of edaravone on acute brainstem-cerebellar infarction with vertigo and sudden hearing loss |
| Q53059139 | Effect of edaravone on apoptosis of hippocampus neuron in seizures rats kindled by pentylenetetrazole. |
| Q46975825 | Effect of edaravone on cerebral vasospasm following experimental subarachnoid hemorrhage |
| Q43096240 | Effect of edaravone on extracellular signal-regulated kinase 1/2 pathway following severe traumatic brain injury in rats |
| Q34465685 | Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry |
| Q33525950 | Effect of edaravone on ischemia/reperfusion injury in rat urinary bladder--changes in smooth muscle cell phenotype and contractile function |
| Q43234450 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction |
| Q34456056 | Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial |
| Q41850883 | Effect of edaravone on serum SP-A and arterial blood gas in patients with lobectomy. |
| Q45099667 | Effect of edaravone on streptomycin-induced vestibulotoxicity in the Guinea pig. |
| Q48152022 | Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease |
| Q93024616 | Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients |
| Q48155636 | Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging |
| Q45100465 | Effect of edaravone, a novel free radical scavenger, on endothelium-dependent vasodilation in smokers |
| Q45998301 | Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: in vitro study of isolated rat heart. |
| Q52149309 | Effect of free radical scavenger, edaravone, for patients with carbon monoxide poisoning. |
| Q44989348 | Effect of methylprednisolone and edaravone administration on spinal cord injury |
| Q48263094 | Effect of prophylactically administered edaravone during antegrade cerebral perfusion in a canine model of old cerebral infarction |
| Q45915217 | Effect of the free radical scavenger edaravone on peripheral nerve ischemia-reperfusion injury. |
| Q48617465 | Effects of Edaravone on Hippocampal Antioxidants in EL Mice |
| Q89957717 | Effects of Edaravone on Neurological Function and Tumor Necrosis Factor Alpha and Interleukin 8 Levels in Patients with Cerebral Infarction |
| Q92285924 | Effects of Edaravone on Nitric Oxide, Hydroxyl Radicals and Neuronal Nitric Oxide Synthase During Cerebral Ischemia and Reperfusion in Mice |
| Q92022133 | Effects of Edaravone on pancreatic and renal injury in rats with severe acute pancreatitis |
| Q80175824 | Effects of MCI-186 (edaravone), a novel free radical scavenger, upon experimental atherosclerosis in apolipoprotein E-deficient mice |
| Q48257378 | Effects of edaravone in heart of aged rats after cerebral ischemia-reperfusion injury |
| Q48424609 | Effects of edaravone on N-methyl-D-aspartate (NMDA)-mediated cytochrome c release and apoptosis in neonatal rat cerebrocortical slices |
| Q48292185 | Effects of edaravone on a rat model of punch-drunk syndrome |
| Q39209409 | Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells |
| Q47718593 | Effects of edaravone on cardiac damage in valproic acid induced toxicity |
| Q92245995 | Effects of edaravone on cerebral ischemia-reperfusion in mice through the TLR4/NF-κB/TNF-α pathway |
| Q51062315 | Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. |
| Q44749630 | Effects of edaravone on experimental brain injury in view of free radical reaction. |
| Q45308223 | Effects of edaravone on human neutrophil function |
| Q36649004 | Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study |
| Q45027825 | Effects of edaravone on reperfusion injury in patients with acute myocardial infarction |
| Q48319664 | Effects of edaravone on singlet oxygen released from activated human neutrophils |
| Q42745179 | Effects of edaravone on the expression of GRP78, Caspase-12, and neuron apoptosis in juvenile rat hippocampus after status convulsive |
| Q43232891 | Effects of edaravone on the expression of interleukin-1beta, nuclear factor-kappaB and neuron apoptosis in juvenile rat hippocampus after status convulsion |
| Q43599288 | Effects of edaravone on the expression of β-defensin-2 mRNA in lung tissue of rats with myocardial ischemia reperfusion |
| Q48496941 | Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase |
| Q55281571 | Effects of edaravone, a free radical scavenger, on photochemically induced cerebral infarction in a rat hemiplegic model. |
| Q83152515 | Effects of edaravone, a free radical scavenger, on serum levels of inflammatory biomarkers in acute brain infarction |
| Q46492859 | Effects of edaravone, a free-radical scavenger, on bleomycin-induced lung injury in mice |
| Q39131849 | Effects of edaravone, a radical scavenger, on hepatocyte transplantation |
| Q44884093 | Effects of edaravone, minocycline and ONO-1078 on oxygen/glucose deprivation-induced electrophysiological alteration in rat hippocampal slices |
| Q52676107 | Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator. |
| Q46718818 | Effects of the free radical scavenger, edaravone, on the development of postoperative cognitive impairment in patients undergoing carotid endarterectomy |
| Q93358794 | Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis |
| Q48593468 | Efficacy of edaravone in cardioembolic stroke |
| Q39012164 | Efficacy of edaravone on coronary artery bypass patients with myocardial damage after ischemia and reperfusion: a meta analysis |
| Q46616411 | Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction |
| Q44459353 | Efficacy of edaravone, a free radical scavenger, on left ventricular function and structure in diabetes mellitus |
| Q46051046 | Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction |
| Q35958898 | Efficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis |
| Q94558252 | Efficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis [Retraction] |
| Q85646228 | Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone |
| Q83926673 | Electron spin resonance and spin trapping technique provide direct evidence that edaravone prevents acute ischemia-reperfusion injury of the liver by limiting free radical-mediated tissue damage |
| Q45987642 | Electrophysiological study on differentiation of rat bone marrow stromal stem cells into neuron-like cells in vitro by edaravone. |
| Q90628396 | Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis |
| Q46749262 | Evaluation of edaravone against radiation-induced oral mucositis in mice |
| Q48239519 | Evaluation of sample preparation and chromatographic separation for the parallel determination of taurine and edaravone in rat tissues using HILIC-MS/MS. |
| Q89612318 | Evaluation of the protective effect of edaravone on doxorubicin nephrotoxicity by [99mTc]DMSA renal scintigraphy and biochemical methods |
| Q40097205 | Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5 |
| Q46820332 | Experimental study on the protective effects of edaravone against ischemic spinal cord injury |
| Q50222468 | Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis |
| Q50222475 | Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). |
| Q44895277 | Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain |
| Q88268738 | FDA approves edaravone for amyotrophic lateral sclerosis |
| Q83320510 | Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger |
| Q49587241 | Formulary Drug Review: Edaravone |
| Q45558891 | Free Radical Scavenger Edaravone Administration Protects against Tissue Plasminogen Activator Induced Oxidative Stress and Blood Brain Barrier Damage |
| Q45209572 | Free radical scavenger (edaravone) prevents endotoxin-induced liver injury after partial hepatectomy in rats |
| Q47886374 | Free radical scavenger edaravone produces robust neuroprotection in a rat model of spinal cord injury |
| Q40061096 | Free radical scavenger edaravone suppresses x-ray-induced apoptosis through p53 inhibition in MOLT-4 cells. |
| Q44921869 | Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion |
| Q34769939 | Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke |
| Q83461790 | Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats |
| Q35319144 | Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats. |
| Q88307912 | Gastric retention pellets of edaravone with enhanced oral bioavailability: Absorption mechanism, development, and in vitro/in vivo evaluation |
| Q48196138 | Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform |
| Q47700268 | How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? |
| Q34628227 | Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate |
| Q90869256 | Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke |
| Q80334827 | Hydroxyl radical scavenging by edaravone derivatives: Efficient scavenging by 3-methyl-1-(pyridin-2-yl)-5-pyrazolone with an intramolecular base |
| Q35060006 | Hydroxypropyl-sulfobutyl-β-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes. |
| Q80175873 | Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial |
| Q57462688 | Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats |
| Q35596149 | Improved brain MRI indices in the acute brain stem infarct sites treated with hydroxyl radical scavengers, Edaravone and hydrogen, as compared to Edaravone alone. A non-controlled study |
| Q95644222 | Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients |
| Q48191907 | Improvement of postischemic dopaminergic dysfunction by edaravone, a free radical scavenger |
| Q46562445 | In vitro metabolism study of edaravone in Wistar and hairless rat skin |
| Q44213912 | In vivo and in vitro treatment with edaravone promotes proliferation of neural progenitor cells generated following neuronal loss in the mouse dentate gyrus |
| Q45350183 | In vivo optical imaging correlates with improvement of cerebral ischemia treated by intravenous bone marrow stromal cells (BMSCs) and edaravone |
| Q84100266 | In vivo optical imaging for evaluating the efficacy of edaravone after transient cerebral ischemia in mice |
| Q45014020 | In vivo radioprotection of mice by 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone; Radicut), a clinical drug |
| Q85631552 | Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration |
| Q42484766 | Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction |
| Q37289134 | Inhibition of fibrosis and inflammation by triple therapy with pirfenidone, edaravone and erythropoietin in rabbits with drug-induced lung injury: comparison of CT imaging and pathological findings |
| Q51581663 | Inhibitory Effects of Edaravone, a Free Radical Scavenger, on Cytokine-induced Hyperpermeability of Human Pulmonary Microvascular Endothelial Cells:A Comparison with Dexamethasone and Nitric Oxide Synthase Inhibitor. |
| Q90250135 | Inhibitory effect of edaravone on systemic inflammation and local damage in skeletal muscles following long-term ischemia to murine hind limb |
| Q37718902 | Inhibitory effects of edaravone in β-amyloid-induced neurotoxicity in rats. |
| Q82894630 | Inhibitory effects of edaravone on the production of tumor necrosis factor-alpha in the isolated heart undergoing ischemia and reperfusion |
| Q45269159 | Intrathecal edaravone, a free radical scavenger, is effective on inflammatory-induced pain in rats |
| Q48120183 | Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. |
| Q54510524 | Investigation of effect of edaravone on ischemic stroke. |
| Q42604593 | Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). |
| Q62071928 | Ionization Energies, Proton Affinities, and pKaValues of a Large Series of Edaravone Derivatives: Implication for Their Free Radical Scavenging Activity |
| Q38642480 | Is Edaravone the Future of Free Radical Scavenging in Inflammatory States? |
| Q58100241 | Is edaravone harmful? (A placebo is not a control) |
| Q47606847 | July 2017 ENCALS statement on edaravone |
| Q35140601 | LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study |
| Q38699643 | Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation |
| Q87144519 | Local administration of lactic acid and a low dose of the free radical scavenger, edaravone, alleviates myocardial reperfusion injury in rats |
| Q95274288 | Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina |
| Q90767965 | Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19) |
| Q55330301 | Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. |
| Q79786705 | Long-term efficacy of edaravone in patients with acute myocardial infarction |
| Q46442481 | Low-dose edaravone injection into the clamped aorta prevents ischemic spinal cord injury |
| Q46539106 | MCI-186 (edaravone), a free radical scavenger, attenuates hepatic warm ischemia-reperfusion injury in rats |
| Q46904534 | MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation |
| Q46650368 | MCI-186 (edaravone), a novel free radical scavenger, protects against acute autoimmune myocarditis in rats |
| Q40924995 | Metabolomic Analyses of Brain Tissue in Sepsis Induced by Cecal Ligation Reveal Specific Redox Alterations--Protective Effects of the Oxygen Radical Scavenger Edaravone |
| Q48726268 | Modifying neurorepair and neuroregenerative factors with tPA and edaravone after transient middle cerebral artery occlusion in rat brain |
| Q46478533 | Multi-center survey of edaravone treatment in children |
| Q92839903 | Myeloperoxidase-mediated oxidation of edaravone produces an apparent non-toxic free radical metabolite and modulates hydrogen peroxide-mediated cytotoxicity in HL-60 cells |
| Q28484248 | Neurodegenerative evidence in mice brains with cecal ligation and puncture-induced sepsis: preventive effect of the free radical scavenger edaravone |
| Q46494037 | Neuroprotection and enhanced recovery with edaravone after acute spinal cord injury in rats |
| Q44972642 | Neuroprotection of edaravone on hypoxic-ischemic brain injury in neonatal rats |
| Q50535099 | Neuroprotection of edaravone on the hippocampus of kainate-induced epilepsy rats through Nrf2/HO-1 pathway. |
| Q40050004 | Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis |
| Q48906601 | Neuroprotective effects of edaravone after intraventricular hemorrhage in rats |
| Q45804897 | Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats |
| Q43271260 | Neuroprotective effects of edaravone on early brain injury in rats after subarachnoid hemorrhage |
| Q46451033 | Neuroprotective effects of edaravone, a free radical scavenger, on the rat hippocampus after pilocarpine-induced status epilepticus |
| Q21262040 | Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons |
| Q33997543 | Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. |
| Q50957200 | Neuroprotective effects of edaravone: recent insights. |
| Q45149531 | Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia |
| Q80600933 | Nitric oxide-induced apoptosis in cultured rat astrocytes: protection by edaravone, a radical scavenger |
| Q44582063 | Normalization by edaravone, a free radical scavenger, of irradiation-reduced endothelial nitric oxide synthase expression |
| Q46871549 | Novel effects of edaravone on human brain microvascular endothelial cells revealed by a proteomic approach |
| Q38851539 | Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents |
| Q91544205 | Nrf2 mediates the protective effect of edaravone after chlorpyrifos-induced nervous system toxicity |
| Q46612066 | OH radical scavenging activity of Edaravone: mechanism and kinetics |
| Q88529561 | Ocrelizumab, edaravone, and valbenazine |
| Q62071917 | On the Outstanding Antioxidant Capacity of Edaravone Derivatives through Single Electron Transfer Reactions |
| Q62071900 | On the hydroperoxyl radical scavenging activity of two Edaravone derivatives: mechanism and kinetics |
| Q62071918 | On the•OH and•OOH scavenging activity of 3-methyl-1-pyridin-2-yl-5-pyrazolone: Comparisons with its parent compound, edaravone |
| Q50222465 | Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis |
| Q46353997 | Outcome assessment in treatment of edaravone in childhood ischemic stroke |
| Q49660804 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes |
| Q64782441 | Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: the Case of Edaravone |
| Q48445689 | Perfluorocarbon-facilitated CNS oxygen toxicity in rats: reversal by edaravone |
| Q38983792 | Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia |
| Q95514877 | Pharmacoeconomic Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of Amyotrophic Lateral Sclerosis (ALS) |
| Q43058450 | Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats |
| Q48033726 | Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations |
| Q44025042 | Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent |
| Q45599632 | Pharmacological postconditioning with lactic acid and low dose edaravone could attenuate myocardial reperfusion injury through mitochondrial pathway |
| Q36650163 | Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions |
| Q39120767 | Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite |
| Q44610359 | Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain |
| Q46359619 | Post-exposure administration of edaravone attenuates noise-induced hearing loss. |
| Q93078870 | Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis |
| Q50222477 | Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis |
| Q48033706 | Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis |
| Q50730228 | Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. |
| Q43079903 | Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. |
| Q91030054 | Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers |
| Q35171343 | Pre- and posttreatment with edaravone protects CA1 hippocampus and enhances neurogenesis in the subgranular zone of dentate gyrus after transient global cerebral ischemia in rats |
| Q89615128 | Predicting the Pharmacokinetic Characteristics of Edaravone Intravenous Injection and Sublingual Tablet Through Modeling and Simulation |
| Q46276329 | Pretreatment with edaravone reduces lung mitochondrial damage in an infant rabbit ischemia-reperfusion model |
| Q55296386 | Pretreatment with the Free Radical Scavenger Edaravone Mitigates Kidney Glycogen Depletion and Neutrophil Infiltration after Leg Ischemia in a Rat Model: A Pilot Study. |
| Q45127691 | Pretreatment with the free radical scavenger edaravone prevents cerebral hyperperfusion after carotid endarterectomy |
| Q80374582 | Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy |
| Q39949233 | Preventive effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced lung injury in mice |
| Q30968894 | Prophylactic Edaravone Prevents Transient Hypoxic-Ischemic Brain Injury: Implications for Perioperative Neuroprotection |
| Q48972975 | Protection by Edaravone, a Radical Scavenger, against Manganese-Induced Neurotoxicity in Rats |
| Q44136581 | Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats |
| Q33547220 | Protection of edaravone on neurons and its effects on the expression of interleukin-lbeta in juvenile rat hippocampus following status convulsion |
| Q46334369 | Protective Effect of Edaravone Against Aβ25-35-Induced Mitochondrial Oxidative Damage in SH-SY5Y Cells |
| Q38866113 | Protective Effect of Edaravone Against Cyclosporine-Induced Chronic Nephropathy Through Antioxidant and Nitric Oxide Modulating Pathways in Rats |
| Q89494301 | Protective Effect of Edaravone Against Oxidative Stress in C2C12 Myoblast and Impairment of Skeletal Muscle Regeneration Exposed to Ischemic Injury in Ob/ob Mice |
| Q37644475 | Protective Effect of Edaravone against Carbon Monoxide Induced Apoptosis in Rat Primary Cultured Astrocytes |
| Q36236194 | Protective Effect of Edaravone in Primary Cerebellar Granule Neurons against Iodoacetic Acid-Induced Cell Injury |
| Q91774684 | Protective Effect of Edaravone on Cyclophosphamide Induced Oxidative Stress and Neurotoxicity in Rats |
| Q30368138 | Protective Effect of Edaravone on Glutamate-Induced Neurotoxicity in Spiral Ganglion Neurons. |
| Q35999736 | Protective Effects of Edaravone in Adult Rats with Surgery and Lipopolysaccharide Administration-Induced Cognitive Function Impairment |
| Q35848920 | Protective effect of Edaravone against hypoxia-induced cytotoxicity in osteoblasts MC3T3-E1 cells |
| Q39249288 | Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells. |
| Q42921522 | Protective effect of edaravone against PrP106-126-induced PC12 cell death |
| Q46763778 | Protective effect of edaravone against endolymphatic hydrops |
| Q41847656 | Protective effect of edaravone against hypoxia-reoxygenation injury in rabbit cardiomyocytes |
| Q35763243 | Protective effect of edaravone against manganese-induced toxicity in cultured rat astrocytes. |
| Q42865619 | Protective effect of edaravone against renal ischemia/reperfusion injury and compared with ischemic postconditioning in rats |
| Q44324451 | Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig. |
| Q46820474 | Protective effect of edaravone against the ototoxicity of Pseudomonas aeruginosa exotoxin A. |
| Q46496616 | Protective effect of edaravone against tobramycin-induced ototoxicity |
| Q34636645 | Protective effect of edaravone for tourniquet-induced ischemia-reperfusion injury on skeletal muscle in murine hindlimb |
| Q46682967 | Protective effect of edaravone in inner-ear barotrauma in guinea pigs |
| Q90291185 | Protective effect of edaravone on blood-brain barrier by affecting NRF-2/HO-1 signaling pathway |
| Q33495329 | Protective effect of edaravone, a free-radical scavenger, on ischaemia-reperfusion injury in the rat testis |
| Q79440043 | Protective effect of radical scavenger edaravone against puromycin nephrosis |
| Q34568490 | Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum |
| Q50034037 | Protective effects of a radical scavenger edaravone on oligodendrocyte precursor cells against oxidative stress. |
| Q44599951 | Protective effects of edaravone against cisplatin-induced hair cell damage in zebrafish |
| Q41351684 | Protective effects of edaravone against cobalt chloride-induced apoptosis in PC12 cells |
| Q46267103 | Protective effects of edaravone against ischemia-induced facial palsy |
| Q51651472 | Protective effects of edaravone combined puerarin on inhalation lung injury induced by black gunpowder smog. |
| Q41941932 | Protective effects of edaravone on diffuse brain injury in rats |
| Q53112827 | Protective effects of edaravone on experimental chronic pancreatitis induced by dibutyltin dichloride in rats. |
| Q83395974 | Protective effects of edaravone on experimental spinal cord injury in rats |
| Q46546235 | Protective effects of edaravone on renal ischemia-reperfusion injury in rats |
| Q41037255 | Protective effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced acute kidney injury in a rat model of sepsis |
| Q42448264 | Protective effects of free radical scavenger edaravone against xanthine oxidase-mediated permeability increases in human intestinal epithelial cell monolayer |
| Q33494069 | Protective effects of the free radical scavenger edaravone against glutamate neurotoxicity in nearly pure neuronal culture |
| Q43207385 | Protective effects of the free radical scavenger edaravone on acute pancreatitis-associated lung injury |
| Q35747347 | Protective role of edaravone against cisplatin-induced ototoxicity in an auditory cell line. |
| Q31160169 | Protective role of edaravone against neomycin-induced ototoxicity in zebrafish. |
| Q81152100 | Pulse radiolysis study on free radical scavenger edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) |
| Q82789731 | Pulse radiolysis study on free radical scavenger edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one). 2: A comparative study on edaravone derivatives |
| Q57038512 | Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone-a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats |
| Q40566384 | Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. |
| Q92305247 | Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch |
| Q86249508 | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) |
| Q46043549 | Reactive oxygen species modulate growth of cerebral aneurysms: a study using the free radical scavenger edaravone and p47phox(-/-) mice. |
| Q28601559 | Recon 2.2: from reconstruction to model of human metabolism |
| Q43225041 | Repeated edaravone treatment reduces oxidative cell damage in rat brain induced by middle cerebral artery occlusion |
| Q33200425 | Research and development of the free radical scavenger edaravone as a neuroprotectant |
| Q38963088 | Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone). |
| Q91979459 | Retrospective study of clinical features and prognosis of edaravone in the treatment of paraquat poisoning |
| Q57169804 | Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs |
| Q39928442 | Role of edaravone in managemant of septic peritonitis |
| Q91219103 | Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial |
| Q92041701 | Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy |
| Q38776278 | Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial |
| Q55686117 | Self-nanomicellizing solid dispersion of edaravone: part I – oral bioavailability improvement. |
| Q60706687 | Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model |
| Q46740162 | Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy |
| Q46105928 | Signaling pathway on the effect of oxygenated warm perfusion prior to cold preservation of the liver grafts from non-heart-beating donors, and the additive effect of edaravone |
| Q89186349 | Simultaneous Blood-Brain Barrier Crossing and Protection for Stroke Treatment Based on Edaravone-Loaded Ceria Nanoparticles |
| Q48488752 | Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients |
| Q89614004 | Simvastatin, edaravone and dexamethasone protect against kainate-induced brain endothelial cell damage |
| Q43239329 | Small temperature variations alter edaravone-induced neuroprotection of cortical cultures exposed to prolonged hypoxic episodes. |
| Q48063832 | Sodium Phenylbutyrate and Edaravone Abrogate Chronic Restraint Stress-Induced Behavioral Deficits: Implication of Oxido-Nitrosative, Endoplasmic Reticulum Stress Cascade, and Neuroinflammation |
| Q30384387 | Solid lipid nanoparticles loaded with edaravone for inner ear protection after noise exposure. |
| Q47135722 | Stabilizers of edaravone aqueous solution and their action mechanisms. 1. Sodium bisulfite |
| Q47137997 | Stabilizers of edaravone aqueous solution and their action mechanisms. 2. Glutathione |
| Q37394086 | Stereotactic Administration of Edaravone Ameliorates Collagenase-Induced Intracerebral Hemorrhage in Rat |
| Q39082753 | Streptozotocin Inhibits Electrophysiological Determinants of Excitatory and Inhibitory Synaptic Transmission in CA1 Pyramidal Neurons of Rat Hippocampal Slices: Reduction of These Effects by Edaravone. |
| Q48443379 | Streptozotocin inhibits synaptic transmission and edaravone attenuates streptozotocin-induced electrophysiological changes in CA1 pyramidal neurons of rat hippocampal slices |
| Q48550169 | Stress degradation of edaravone: Separation, isolation and characterization of major degradation products |
| Q35576397 | Striatal neuroprotection from neonatal hypoxia-ischemia in piglets by antioxidant treatment with EUK-134 or edaravone |
| Q51489791 | Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. |
| Q91276525 | Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties |
| Q44560101 | Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone). |
| Q35534917 | Study on the interaction of plasma protein binding rate between edaravone and taurine in human plasma based on HPLC analysis coupled with ultrafiltration technique |
| Q34268115 | Suppression of oxidative stress and 5-lipoxygenase activation by edaravone improves depressive-like behavior after concussion |
| Q34220735 | Suppression of postoperative intimal hyperplasia of vein grafts with edaravone in rat models - a scanning electron microscope study |
| Q46118701 | Survivin is involved in the anti-apoptotic effect of edaravone in PC12 cells |
| Q95360310 | Synaptic Plasticity of Human Umbilical Cord Mesenchymal Stem Cell Differentiating into Neuron-like Cells In Vitro Induced by Edaravone |
| Q28539510 | Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke |
| Q44560104 | Synthesis of the metabolites of a free radical scavenger edaravone (MCI-186, Radicut). |
| Q59545441 | Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs |
| Q92343944 | Synthesis, Characterization and Antioxidant Properties of a New Lipophilic Derivative of Edaravone |
| Q39631651 | Synthesis, antitumor activity and QSAR studies of some 4-aminomethylidene derivatives of edaravone |
| Q52876332 | Synthesis, molecular properties prediction and anticancer, antioxidant evaluation of new edaravone derivatives. |
| Q43017896 | Systemic administration of a free radical scavenger, edaravone, protects against light-induced photoreceptor degeneration in the mouse retina |
| Q35078682 | Targeting reactive oxygen species by edaravone inhalation in a rat hyperoxic lung injury model: role of inflammasome |
| Q46445607 | Temporal effects of edaravone, a free radical scavenger, on transient ischemia-induced neuronal dysfunction in the rat hippocampus |
| Q91504884 | The active participation of p22phox-214T/C in the formation of intracranial aneurysm and the suppressive potential of edaravone |
| Q42918164 | The antioxidant edaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction in rats with autoimmune myocarditis |
| Q46433002 | The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy |
| Q39633634 | The antioxidant edaravone prevents cardiac dysfunction by suppressing oxidative stress in type 1 diabetic rats and in high-glucose-induced injured H9c2 cardiomyoblasts |
| Q44544616 | The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction |
| Q44806860 | The clinical free radical scavenger, edaravone, protects cochlear hair cells from acoustic trauma. |
| Q33628145 | The combined use of edaravone, diuretics, and nonsteroidal anti-inflammatory drugs caused acute kidney injury in an elderly patient with chronic kidney disease |
| Q36044786 | The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats |
| Q51351170 | The effect of edaravone on ischemia-reperfusion injury in rat ovary. |
| Q47383862 | The effects of edaravone in ketamine-induced model of mania in rats. |
| Q27015129 | The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease |
| Q46085087 | The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. |
| Q44469421 | The free radical scavenger edaravone suppresses experimental closed duodenal loop-induced acute pancreatitis in rats |
| Q44469424 | The free radical scavenger edaravone suppresses experimental dextran sulfate sodium-induced colitis in rats |
| Q53101197 | The free radical scavenger, edaravone, ameliorates delayed neuropsychological sequelae after acute carbon monoxide poisoning in rabbits. |
| Q46878537 | The free radical scavengers edaravone and tempol suppress experimental dextran sulfate sodium-induced colitis in mice. |
| Q35613302 | The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model |
| Q80818824 | The free-radical scavenger edaravone restores the differentiation of human neural precursor cells after radiation-induced oxidative stress |
| Q33243521 | The free-radical scavenger, edaravone, augments NO release from vascular cells and platelets after laser-induced, acute endothelial injury in vivo. |
| Q46318985 | The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator |
| Q46591722 | The novel antioxidant edaravone: from bench to bedside |
| Q45933136 | The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury. |
| Q90508006 | The protective effect of edaravone on memory impairment induced by chronic sleep deprivation |
| Q43204787 | The protective effect of edaravone on the treatment of sepsis in rats |
| Q40047050 | The radical scavenger edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) reacts with a pterin derivative and produces a cytotoxic substance that induces intracellular reactive oxygen species generation and cell death |
| Q46740665 | The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice |
| Q40386261 | The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB. |
| Q46808170 | The radical scavenger edaravone improves neurologic function and perihematomal glucose metabolism after acute intracerebral hemorrhage |
| Q45253597 | The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. |
| Q44752604 | The reaction rate of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186)) with hydroxyl radical |
| Q46856874 | The role of edaravone on the impairment of endothelial barrier function induced by acute oxidative stress in cultured human umbilical vein endothelial cell monolayer |
| Q53579670 | The specific free radical scavenger edaravone suppresses bleomycin-induced acute pulmonary injury in rabbits. |
| Q84207297 | The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis |
| Q43964110 | The study of the protective effect and its mechanism of Edaravone to neurons with hydrogen peroxide stimulated |
| Q48687849 | The synergetic effect of edaravone and borneol in the rat model of ischemic stroke |
| Q90623978 | The therapeutic effects of edaravone on collagen-induced arthritis in rats |
| Q79250271 | The therapeutic efficacy of edaravone in extensively burned rats |
| Q56782310 | Theoretical insights on the antioxidant activity of edaravone free radical scavengers derivatives |
| Q46018354 | Therapeutic effect of edaravone on inner ear barotrauma in the guinea pig. |
| Q58920601 | Therapeutic time window for edaravone treatment of traumatic brain injury in mice |
| Q82673279 | Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury |
| Q80275605 | Treatment with edaravone improves the survival rate in renal warm ischemia-reperfusion injury using rat model |
| Q46418017 | Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice |
| Q88437167 | Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics |
| Q57149054 | Two complementary liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods to study the excretion and metabolic interaction of edaravone and taurine in rats |
| Q90350400 | Two high-performance liquid chromatography-tandem mass spectrometry methods for determination of edaravone and taurine in human plasma: Application to drug-drug interaction and pharmacokinetic studies |
| Q87043198 | UPEI-300, a conjugate of lipoic acid and edaravone, mediates neuroprotection in ischemia/reperfusion |
| Q80034153 | Urgent endarterectomy using pretreatment with free radical scavenger, edaravone, and early clamping of the parent arteries for cervical carotid artery stenosis with crescendo transient ischemic attacks caused by mobile thrombus and hemodynamic cereb |
| Q48489431 | WITHDRAWN: Edaravone protects brain tissue from apoptosis and oxidative stress after acute carbon monoxide poisoning |
| Q50222481 | What can we learn from the edaravone development program for ALS? |
| Q38381824 | YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy). |
| Q45950769 | [Edaravone protects hearing from acute acoustic trauma in guinea pigs]. |
| Q91269541 | [Edaravone: A New Treatment for ALS] |
| Q80222103 | [Edaravone] |
| Q53264020 | [Effect of edaravone on oxidative stress and myocardial fibrosis induced by isoproterenol in rats]. |
| Q45950794 | [Effects of edaravone on IRE1 mRNA expression and neuronal apoptosis in the hippocampus of rats with status convulsivus]. |
| Q83680906 | [Effects of edaravone on glial fibrillary acidic protein and interleukin-lβ expression and neuronal apoptosis in juvenile rat hippocampus after status convulsion] |
| Q83416015 | [Effects of intraoperative application of radical scavenger edaravone in severe elderly cases] |
| Q83145111 | [Homeostatic conditions affect the protective effect of edaravone on ischemic injury in neurons] |
| Q50509908 | [Intervention of edaravone against renal injury induced by acute paraquat poisoning in rats]. |
| Q53168739 | [Neuroprotective effects of combined pretreatment with edaravone and propofol on neonatal rat cerebral cortical neurons with ischemia/reperfusion injury in vitro]. |
| Q93200967 | [Protective effect of edaravone on balance of mitochondrial fusion and fission in MPP+-treated PC12 cells] |
| Q84835204 | [Stimulative effect of edaravone on growth of neuronal stem cells and precursor cells following lesioning of hippocampal dentate gyrus] |
| Q53522902 | [The effect of edaravone on MAPKs signal pathway associated with Abeta(25-35) treatment in PC12 cells]. |
| Q53143164 | [The pulmonary injury in rats caused by chronic intermittent hypoxia and the intervention effect of Edaravone]. |
| Q39007579 | cRGD mediated liposomes enhanced antidepressant-like effects of edaravone in rats |
| Q206901 | amyotrophic lateral sclerosis | drug or therapy used for treatment | P2176 |
| Q47522060 | Radicava | has active ingredient | P3781 |
| Category:Edaravone | wikimedia | |
| 3-Methyl-1-phenyl-5-pyrazolon | wikipedia | |
| Edaravone | wikipedia | |
| Persian (fa / Q9168) | اداراوون | wikipedia |
| Édaravone | wikipedia | |
| エダラボン | wikipedia | |
| 에다라본 | wikipedia | |
| 1-Фенил-3-метил-5-пиразолон | wikipedia | |
| Serbo-Croatian (sh / Q9301) | Edaravon | wikipedia |
| Edaravon | wikipedia | |
| Едаравон | wikipedia | |
| 依达拉奉 | wikipedia |
Search more.